BR112021022527A2 - Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos - Google Patents
Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmosInfo
- Publication number
- BR112021022527A2 BR112021022527A2 BR112021022527A BR112021022527A BR112021022527A2 BR 112021022527 A2 BR112021022527 A2 BR 112021022527A2 BR 112021022527 A BR112021022527 A BR 112021022527A BR 112021022527 A BR112021022527 A BR 112021022527A BR 112021022527 A2 BR112021022527 A2 BR 112021022527A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- zuranolone
- brexanolone
- ganaxolone
- composition containing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- PGTVWKLGGCQMBR-FLBATMFCSA-N Ganaxolone Chemical compound C([C@@H]1CC2)[C@](C)(O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 PGTVWKLGGCQMBR-FLBATMFCSA-N 0.000 title abstract 2
- AURFZBICLPNKBZ-SYBPFIFISA-N brexanolone Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-SYBPFIFISA-N 0.000 title abstract 2
- 229950009652 brexanolone Drugs 0.000 title abstract 2
- 229950006567 ganaxolone Drugs 0.000 title abstract 2
- HARRKNSQXBRBGZ-GVKWWOCJSA-N zuranolone Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CC[C@@](C)(O)C[C@H]4CC3)CC[C@@]21C)CN1C=C(C#N)C=N1 HARRKNSQXBRBGZ-GVKWWOCJSA-N 0.000 title abstract 2
- 229940121642 zuranolone Drugs 0.000 title abstract 2
- 229940124277 aminobutyric acid Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos das mesmas. a presente invenção refere-se a uma composição farmacêutica que compreende uma quantidade farmaceuticamente eficaz de um esteroide neuroativo que é um modulador positivo de receptores de ácido ¿ aminobutírico tipo a (gabaa). a presente invenção também se refere a métodos de tratamento de doenças que usam a composição farmacêutica e processos de produção da composição farmacêutica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962846576P | 2019-05-10 | 2019-05-10 | |
US202063018815P | 2020-05-01 | 2020-05-01 | |
PCT/US2020/032172 WO2020231837A1 (en) | 2019-05-10 | 2020-05-08 | Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021022527A2 true BR112021022527A2 (pt) | 2021-12-28 |
Family
ID=73288816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021022527A BR112021022527A2 (pt) | 2019-05-10 | 2020-05-08 | Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220241295A1 (pt) |
EP (1) | EP3965772A4 (pt) |
JP (1) | JP2022532710A (pt) |
KR (1) | KR20220006565A (pt) |
CN (1) | CN113939299A (pt) |
AU (1) | AU2020275291A1 (pt) |
BR (1) | BR112021022527A2 (pt) |
CA (1) | CA3138901A1 (pt) |
IL (1) | IL287905A (pt) |
MX (1) | MX2021013695A (pt) |
SG (1) | SG11202112111WA (pt) |
TW (2) | TW202344255A (pt) |
WO (1) | WO2020231837A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL295902A (en) * | 2020-02-27 | 2022-10-01 | Brii Biosciences Inc | Drug inhibitors of neuroactive steroids |
CN116348095A (zh) * | 2020-08-17 | 2023-06-27 | 腾盛博药生物科技有限公司 | 含有神经活性类固醇的药物组合物及其用途 |
CN112516086B (zh) * | 2020-12-08 | 2022-05-20 | 武汉久安药物研究院有限公司 | 注射用布瑞诺龙脂肪乳及其制备方法 |
WO2022155507A1 (en) * | 2021-01-15 | 2022-07-21 | Jubilant Pharma Holdings Inc. | Transmucosal dosage forms of brexanolone |
WO2023092046A1 (en) * | 2021-11-18 | 2023-05-25 | Brii Biosciences, Inc. | Process and therapeutic composition for treating and preventing severe injection site reactions |
US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
WO2024085245A1 (ja) * | 2022-10-21 | 2024-04-25 | 国立大学法人高知大学 | 術後せん妄の抑制薬 |
CN115957332B (zh) * | 2022-11-01 | 2023-10-10 | 北京华睿鼎信科技有限公司 | 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008006888A (es) * | 2005-11-28 | 2008-09-30 | Marinus Pharmaceuticals | Formulas y metodos para la manufactura y uso de la ganaxolona. |
CA2973140A1 (en) * | 2015-02-06 | 2016-08-11 | Marinus Pharmaceuticals, Inc. | Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders |
EA036155B1 (ru) * | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
CA3060255A1 (en) * | 2017-04-18 | 2018-10-25 | Marinus Pharmaceuticals, Inc | Sustained release injectable neurosteroid formulations |
-
2020
- 2020-05-08 AU AU2020275291A patent/AU2020275291A1/en active Pending
- 2020-05-08 BR BR112021022527A patent/BR112021022527A2/pt unknown
- 2020-05-08 CN CN202080042380.9A patent/CN113939299A/zh active Pending
- 2020-05-08 WO PCT/US2020/032172 patent/WO2020231837A1/en unknown
- 2020-05-08 EP EP20805552.5A patent/EP3965772A4/en active Pending
- 2020-05-08 SG SG11202112111WA patent/SG11202112111WA/en unknown
- 2020-05-08 US US17/610,236 patent/US20220241295A1/en active Pending
- 2020-05-08 KR KR1020217039658A patent/KR20220006565A/ko unknown
- 2020-05-08 CA CA3138901A patent/CA3138901A1/en active Pending
- 2020-05-08 JP JP2021566976A patent/JP2022532710A/ja active Pending
- 2020-05-08 MX MX2021013695A patent/MX2021013695A/es unknown
- 2020-05-11 TW TW112103512A patent/TW202344255A/zh unknown
- 2020-05-11 TW TW109115629A patent/TWI793419B/zh active
-
2021
- 2021-11-08 IL IL287905A patent/IL287905A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113939299A (zh) | 2022-01-14 |
CA3138901A1 (en) | 2020-11-19 |
WO2020231837A1 (en) | 2020-11-19 |
JP2022532710A (ja) | 2022-07-19 |
TW202344255A (zh) | 2023-11-16 |
EP3965772A4 (en) | 2023-05-10 |
IL287905A (en) | 2022-01-01 |
AU2020275291A1 (en) | 2021-11-25 |
MX2021013695A (es) | 2022-01-26 |
EP3965772A1 (en) | 2022-03-16 |
TW202108146A (zh) | 2021-03-01 |
TWI793419B (zh) | 2023-02-21 |
US20220241295A1 (en) | 2022-08-04 |
SG11202112111WA (en) | 2021-11-29 |
KR20220006565A (ko) | 2022-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021022527A2 (pt) | Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos | |
BR112021015238A2 (pt) | Novos anticorpos de ligação a cd40 | |
BR112022012594A2 (pt) | Dosagem de gama-hidroxibutirato (ghb) | |
EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
CL2020001495A1 (es) | Composiciones y método para el tratamiento de enfermedades metabólicas | |
BR112018070852A2 (pt) | composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas | |
BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
BR112017022008A2 (pt) | composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios | |
CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
BR112018005861A2 (pt) | derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos | |
BR112016013734A2 (pt) | Composto, composição farmacêutica, kit, e uso de um composto | |
EA201890859A1 (ru) | Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот | |
BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
BR112019006216A2 (pt) | compostos de p2x3 e/ou p2x2/3 e métodos | |
BR112018000242A2 (pt) | composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico | |
BR112015029897A2 (pt) | composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição | |
AR120717A1 (es) | Análogos de insulina y usos de los mismos | |
BR112018067554A2 (pt) | formulações de testosterona e métodos de tratamento com as mesmas | |
BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
MX2023014484A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
BR112022013322A2 (pt) | Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina | |
BR112017015613A2 (pt) | gel intestinal de levodopa e carbidopa e métodos de utilização | |
BR112023024741A2 (pt) | Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos | |
BR112021009616A8 (pt) | Composição cicatrizante que compreende água eletrolisada e máscara de aplicação cutânea |